Drug Profile


Alternative Names: Deuterated pirfenidone; Deuterium-substituted pirfenidone; Pirfenidone deuterated; SD-560

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Auspex Pharmaceuticals
  • Developer Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antifibrotics; Organic deuterium compounds; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Idiopathic pulmonary fibrosis

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in USA (PO)
  • 05 May 2015 Auspex Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
  • 16 Dec 2014 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top